Developing RNAi Therapeutics for Treatment of Cancer & Fibrosis Diseases

READ MORE

LATEST NEWS

June 16, 2021
Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against... READ MORE
April 28, 2021
Sirnaomics Enters Partnership with Walvax Biotechnology to Co-Develop Its Antiviral RNAi Therapeutic Product Candidate STP702 Sirnaomics Biopharmaceuticals (Suzhou) Co. Ltd., a subsidiary of Sirnaomics, Inc., a biopharmaceutical company engaged in... READ MORE
April 26, 2021
Sirnaomics Initiates Phase 2b Study Using STP705 for Treatment of Squamous Cell Skin Cancer Company Expects to Report Initial Clinical Data in Second Half of 2021 Sirnaomics, Inc., a... READ MORE
April 21, 2021
Sirnaomics’ Spin-Off RNAimmune Secures $10 Million Seed Financing to Advance its mRNA-Based Vaccine and Therapeutic Development RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines,... READ MORE
April 18, 2021
Sirnaomics Initiates Phase 2 Study Using STP705 for Keloid Scar Prevention Company Expects to Report Interim Clinical Data in the Second Half of 2021 Sirnaomics, Inc.,... READ MORE

Science

Our team uses a consistent, validated approach to develop novel siRNA based therapeutics for significant markets with high unmet clinical need. Using a proprietary algorithm for siRNA sequence prediction against known gene targets we can rapidly identify siRNAs for use against traditionally "non-drugable" targets ...

Read More

Pipeline

Sirnaomics is leveraging an unsurpassed level of knowledge and experience in RNA interference (RNAi) technology and forging a path to high value creation with exciting clinical product development programs in multiple therapeutic areas...

Read More
U.S.A  •  China
© 2007-2021 by Sirnaomics, Inc.
Contact